{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:52:15Z","timestamp":1792155135487,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.juro.2013.03.030","type":"journal-article","created":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T00:06:30Z","timestamp":1363392390000},"page":"850-856","source":"Crossref","is-referenced-by-count":112,"title":["Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-\u03b12b Formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin Failures in Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1097","volume":"190","author":[{"given":"Colin P.N.","family":"Dinney","sequence":"first","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cutler","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Young","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Hutchins","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Caceres","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Kishnani","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sode","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Cullen","sequence":"additional","affiliation":[{"name":"Merck, Sharp and Dohme Corp., Upper Gwynedd, Pennsylvania, Union and Kenilworth, New Jersey, and Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Barton","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kincaid","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ainslie","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Maneval","sequence":"additional","affiliation":[{"name":"Halozyme Therapeutics Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Wszolek","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Benedict","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.03.030_bib1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib6","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Gu\u00e9rin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.03.030_bib7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O'Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","article-title":"Superficial bladder cancer: the role of interferon-alpha","volume":"159","author":"Belldegrun","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.03.030_bib10","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1200\/JCO.2003.09.138","article-title":"Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase 1 study of p53 gene therapy","volume":"21","author":"Pagliaro","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.03.030_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.gt.3301348","article-title":"Identification of polyamides that enhance adenovirous-mediated gene expression in the urothelium","volume":"8","author":"Connor","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","article-title":"Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene transfer of genetically altered urothelium and superficial bladder cancer","volume":"9","author":"Yamashita","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFN alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.03.030_bib16","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1158\/0008-5472.CAN-04-1909","article-title":"Autocrine TRAIL production mediates interferon-induced apoptosis in human bladder cancer cells","volume":"64","author":"Papageorgiou","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2013.03.030_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/cgt.2009.2","article-title":"Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker","volume":"16","author":"Fisher","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.cgt.7701011","article-title":"Adenoviral-mediated interferon \u03b1 overcomes resistance to the interferon protein in various cancer types and has marked bystander effects","volume":"14","author":"Zhang","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib19","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/cgt.2008.53","article-title":"Conditioned medium from Ad-IFN-alpha- infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect","volume":"12","author":"Zhang","year":"2008","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/cgt.2010.76","article-title":"Direct gene transfer of adenoviral-mediated interferon-\u03b1 into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity","volume":"18","author":"Zhang","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.juro.2013.03.030_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/cgt.2011.26","article-title":"Direct cytotoxicity produced by adenoviral-mediated interferon \u03b1 infection in interferon resistant cancer cells Involves ER stress and caspase 4 activation","volume":"18","author":"Yang","year":"2011","journal-title":"Cancer Gene Ther"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713036768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713036768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.03.030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:25:03Z","timestamp":1651188303000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.03.030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1016\/j.juro.2013.03.030"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.03.030","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}